The American Society of Clinical Oncology, of Alexandria, Va., named Margaret Tempero president.

Angiogenix Inc., of Burlingame, Calif., added William Spickler as vice president of pharmaceutical development.

AnVil Inc., of Burlington, Mass., added Ronald Lindsay to its board.

Avanir Pharmaceuticals Inc., of San Diego, elected Charles Mathews, Harold Oberkfell and Stephen Austin as class II directors.

GB Therapeutics Ltd., of Mississauga, Ontario, appointed Mark de Somer executive vice president of research and development.

Genentech Inc., of South San Francisco, appointed Philippa Norman vice president, global supply chain.

ImClone Systems Inc., of New York, appointed John Fazio to its board and audit committee.

ISTA Pharmaceuticals Inc., of Irvine, Calif., added Lauren Silvernail as chief financial officer and vice president of corporate development.

Large Scale Biology Corp., of Vacaville, Calif., added Ralph Di Libero as senior director, business development and vice president, sales for its biomanufacturing division.

Ligand Pharmaceuticals Inc., of San Diego, elected John Kozarich to its board.

Maxygen Inc., of Redwood City, Calif., said its subsidiary, Maxygen ApS, appointed Elliot Goldstein senior vice president, clinical development and Denmark operations.

Nektar Therapeutics, of San Carlos, Calif., named Brigid Makes vice president of operations management and Ajay Bansal chief financial officer.

Nereus Pharmaceuticals Inc., of San Diego, added Sanford Madigan as vice president of corporate development and Jennifer Grodberg as director of infectious diseases. Samuel Danishefsky was appointed to its scientific advisory board.

Neurion Pharmaceuticals Inc., of Pasadena, Calif., appointed Michael Sanguinetti to its scientific advisory board.

Novacea Inc., of South San Francisco, appointed William Henner vice president, oncology, and Karen Hartwig vice president, marketing.

Odyssey Thera Inc., of San Ramon, Calif., added Louis Ignarro to its board.

Ortec International Inc., of New York, appointed Ron Lipstein CEO.

Oxis International Inc., of Portland, Ore., named Glenn Poe to head its animal health profiling operations.

PhageTech Inc., of Montreal, appointed Daniel Delorme vice president of chemistry and hired Michel Harpin as director of business development.

Radius Ventures, of New York, added George Milne to its team.

RedStorm Scientific, of Houston, appointed John Carpenter and Joshua Wand to its scientific advisory board.

Thios Pharmaceuticals Inc., of Emeryville, Calif., appointed Bruce Hironaka CEO and named him to its board.

Tm Bioscience Corp., of Toronto, appointed Bradley Popovich to chair its scientific advisory board and also as a member of its board of directors.

United Therapeutics Corp., of Silver Spring, Md., added Paul Gray to its board. He will serve as chairman of the audit committee.